BR112012028368B8 - Processo para prevenção de aglomeração de partículas de ingrediente ativo em uma suspensão, suspensão e composição de torta contendo derivado carbo estirila e óleo de silicone e/ou derivado de óleo de silicone - Google Patents

Processo para prevenção de aglomeração de partículas de ingrediente ativo em uma suspensão, suspensão e composição de torta contendo derivado carbo estirila e óleo de silicone e/ou derivado de óleo de silicone

Info

Publication number
BR112012028368B8
BR112012028368B8 BR112012028368A BR112012028368A BR112012028368B8 BR 112012028368 B8 BR112012028368 B8 BR 112012028368B8 BR 112012028368 A BR112012028368 A BR 112012028368A BR 112012028368 A BR112012028368 A BR 112012028368A BR 112012028368 B8 BR112012028368 B8 BR 112012028368B8
Authority
BR
Brazil
Prior art keywords
suspension
derivative
silicone oil
active ingredient
aglomeration
Prior art date
Application number
BR112012028368A
Other languages
English (en)
Other versions
BR112012028368B1 (pt
BR112012028368A2 (pt
Inventor
Hiraoka Shogo
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44645176&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012028368(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of BR112012028368A2 publication Critical patent/BR112012028368A2/pt
Publication of BR112012028368B1 publication Critical patent/BR112012028368B1/pt
Publication of BR112012028368B8 publication Critical patent/BR112012028368B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Colloid Chemistry (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Disinfection, Sterilisation Or Deodorisation Of Air (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Degasification And Air Bubble Elimination (AREA)
  • Medicinal Preparation (AREA)
  • General Preparation And Processing Of Foods (AREA)

Abstract

SUSPENSÃO E COMPOSIÇÃO DE TORTA CONTENDO DERIVADO CARBO ESTIRILA E ÓLEO DE SILICONE E/OU DERIVADO DE ÓLEO DE SILICONE. A presente invenção refere-se a uma suspensão e uma composição de torta que são providas nas quais aglomeração do ingrediente ativo que é causada quando óleo de silicone e/ou derivado de óleo de silicone está ali contido pode ser suprimida sem um tratamento especial, tal como sonificação. A suspensão contém, em um meio de dispersão, o ingrediente ativo de um específico tamanho médio de partícula primária, e óleo de silicone e/ou derivado de óleo de silicone. A composição de torta contém um ingrediente ativo de um específico tamanho médio de partícula, e óleo de silicone e/ou derivado de óleo de silicone.
BR112012028368A 2010-08-24 2011-08-19 Processo para prevenção de aglomeração de partículas de ingrediente ativo em uma suspensão, suspensão e composição de torta contendo derivado carbo estirila e óleo de silicone e/ou derivado de óleo de silicone BR112012028368B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010187107 2010-08-24
JP2010-187107 2010-08-24
PCT/JP2011/069243 WO2012026562A1 (en) 2010-08-24 2011-08-19 Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative

Publications (3)

Publication Number Publication Date
BR112012028368A2 BR112012028368A2 (pt) 2017-03-21
BR112012028368B1 BR112012028368B1 (pt) 2020-08-04
BR112012028368B8 true BR112012028368B8 (pt) 2022-07-19

Family

ID=44645176

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012028368A BR112012028368B8 (pt) 2010-08-24 2011-08-19 Processo para prevenção de aglomeração de partículas de ingrediente ativo em uma suspensão, suspensão e composição de torta contendo derivado carbo estirila e óleo de silicone e/ou derivado de óleo de silicone

Country Status (20)

Country Link
US (2) US9511022B2 (pt)
EP (1) EP2552420B1 (pt)
JP (1) JP5575269B2 (pt)
KR (1) KR101461769B1 (pt)
CN (1) CN103025318B (pt)
AR (1) AR082494A1 (pt)
AU (1) AU2011294201B2 (pt)
BR (1) BR112012028368B8 (pt)
CA (1) CA2796755C (pt)
CO (1) CO6640304A2 (pt)
ES (1) ES2685469T3 (pt)
IL (1) IL222628A (pt)
MX (1) MX344235B (pt)
MY (1) MY174552A (pt)
NZ (1) NZ603076A (pt)
RU (1) RU2535089C2 (pt)
SG (1) SG184879A1 (pt)
TW (1) TWI589301B (pt)
UA (1) UA107031C2 (pt)
WO (1) WO2012026562A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI632921B (zh) * 2011-10-19 2018-08-21 大塚製藥股份有限公司 口服溶液
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
TWI562991B (en) 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
AR091349A1 (es) * 2012-04-30 2015-01-28 Otsuka Pharma Co Ltd Formulacion oral
CN106474058B (zh) * 2015-08-31 2020-01-07 南京诺瑞特医药科技有限公司 具有延长的保质期的阿立哌唑可注射悬浮液制剂
EP3577111A1 (en) 2017-02-02 2019-12-11 Hexal Aktiengesellschaft Crystalline brexpiprazole
CN114786724A (zh) 2019-12-16 2022-07-22 尼普洛株式会社 防聚集剂以及使用该防聚集剂的药物组合物和医疗用设备

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2827566A1 (de) * 1978-06-23 1980-01-10 Boehringer Mannheim Gmbh 1,2-dihydro-chinolin-2-on-derivate und verfahren zu ihrer herstellung
US4225456A (en) 1978-11-06 1980-09-30 Diamond Shamrock Corporation Water-in-oil emulsion defoamer compositions, their preparation and use
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP3332426B2 (ja) 1992-10-02 2002-10-07 太田製薬株式会社 大腸および小腸の検査用ｘ線造影剤
US5538989A (en) * 1993-11-10 1996-07-23 Hoechst-Roussel Agri-Vet Company Fenbendazole formulations
JP4012994B2 (ja) * 1996-05-08 2007-11-28 大塚製薬株式会社 抗不安薬
JP3952681B2 (ja) 2000-10-10 2007-08-01 味の素株式会社 分岐鎖アミノ酸を含有する医薬用懸濁剤
JP2003081882A (ja) 2001-09-10 2003-03-19 Kyosei Seiyaku Kk 硫酸バリウムｘ線造影剤
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
CN100518806C (zh) 2003-10-02 2009-07-29 兴和株式会社 医药组合物
TWI371274B (en) 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
JP4836797B2 (ja) 2003-10-23 2011-12-14 大塚製薬株式会社 放出制御性無菌注射アリピプラゾール製剤および方法
EP1677762A1 (en) * 2003-10-27 2006-07-12 Dow Corning Corporation A controlled-release composition for topical application and a method of delivering an active agent to a substrate
GB0328693D0 (en) * 2003-12-11 2004-01-14 Ici Plc Metal oxide dispersions
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
NZ561375A (en) * 2005-06-27 2011-06-30 Biovail Lab Int Srl Bupropion hydrobromide, and crystalline forms, compositions, and uses of this compound
JP2009508859A (ja) 2005-09-15 2009-03-05 エラン ファーマ インターナショナル リミテッド ナノ粒子アリピプラゾール製剤
JP4373983B2 (ja) 2006-01-27 2009-11-25 三菱電機インフォメーションシステムズ株式会社 流通経路管理装置及び流通経路管理プログラム
MX2009003737A (es) * 2006-10-05 2009-06-16 Panacea Biotec Ltd Composicion inyectable en deposito y su procedimiento de preparacion.
JP4540700B2 (ja) * 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
EP2101735A2 (en) 2006-11-28 2009-09-23 Marinus Pharmaceuticals, Inc. Nanoparticulate formulations and methods for the making and use thereof
DK2170279T3 (en) * 2007-07-31 2018-03-12 Otsuka Pharma Co Ltd PROCEDURES FOR PREPARING AN ARIPIPRAZOL SUSPENSION AND A FREEZER DRIED FORMULATION
JP2011136906A (ja) * 2008-04-18 2011-07-14 Otsuka Pharmaceut Co Ltd 複素環化合物
JP2010013364A (ja) 2008-07-01 2010-01-21 Tsujido Chemical Corp 高尿酸血症の予防または改善剤

Also Published As

Publication number Publication date
RU2535089C2 (ru) 2014-12-10
TWI589301B (zh) 2017-07-01
CO6640304A2 (es) 2013-03-22
CN103025318B (zh) 2016-07-06
NZ603076A (en) 2014-12-24
IL222628A0 (en) 2012-12-31
US9511022B2 (en) 2016-12-06
BR112012028368B1 (pt) 2020-08-04
JP2013525263A (ja) 2013-06-20
WO2012026562A1 (en) 2012-03-01
IL222628A (en) 2017-10-31
AU2011294201A1 (en) 2012-11-08
EP2552420A1 (en) 2013-02-06
KR101461769B1 (ko) 2014-11-13
SG184879A1 (en) 2012-11-29
MX344235B (es) 2016-12-07
CN103025318A (zh) 2013-04-03
EP2552420B1 (en) 2018-07-18
JP5575269B2 (ja) 2014-08-20
US20170112830A1 (en) 2017-04-27
RU2013113033A (ru) 2014-09-27
US20130045250A1 (en) 2013-02-21
ES2685469T3 (es) 2018-10-09
BR112012028368A2 (pt) 2017-03-21
CA2796755C (en) 2015-10-27
UA107031C2 (uk) 2014-11-10
AU2011294201B2 (en) 2015-08-27
MY174552A (en) 2020-04-24
AR082494A1 (es) 2012-12-12
TW201212940A (en) 2012-04-01
KR20120136415A (ko) 2012-12-18
CA2796755A1 (en) 2012-03-01
MX2012014646A (es) 2013-02-07

Similar Documents

Publication Publication Date Title
BR112012028368B8 (pt) Processo para prevenção de aglomeração de partículas de ingrediente ativo em uma suspensão, suspensão e composição de torta contendo derivado carbo estirila e óleo de silicone e/ou derivado de óleo de silicone
AR117001A2 (es) Formulación de premezcla de dexmedetomidina
BR112017008720A2 (pt) métodos e composições relacionados a nanoveículos sintéticos com rapamicina em um estado supersaturado, estável
WO2014028597A3 (en) 3-CYCLOHEXENYL AND CYCLOHEXYL SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
BR112015027134A8 (pt) método e aditivo para mudar o comportamento reológico de uma formulação à base de água ou à base de álcool, composição e método para estabilizar uma formulação ou aumentar a fotoestabilidade de compostos orgânicos
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
CO6280502A2 (es) Una composicion farmaceutica
WO2014044461A3 (de) Stabilisierung von kapselsystemen in wasch- und reinigungsmitteln
BR112014030812A2 (pt) "compostos tricíclicos substituídos como inibidores de fgfr, seus usos, composição farmacêutica e método para inibir uma enzima fgfr"
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
BR112015012469A2 (pt) pó formado de partículas, mais do que 95% em número de ditas partículas exibindo uma circularidade superior ou igual a 0,85, processo para a fabricação de um pó, processo de pulverização térmica e câmara de tratamento para semicondutores
BR112015004185A2 (pt) composições antiperspirantes em aerossol, produtos e métodos
GEP20186852B (en) Compositions comprising short-acting benzodiazepines
WO2012157978A3 (ko) 팥꽃나무 추출물, 이의 분획물 또는 이로부터 분리한 화합물을 유효성분으로 함유하는 아토피 예방 또는 치료용 약학적 조성물
MX363379B (es) Formulaciones tópicas estabilizadas que contienen microcápsulas de núcleo-cubierta.
BR112012032193A2 (pt) composto, composiçoes e métodos de uso de feniltioacetato
WO2013093869A3 (en) Gel-type cosmetic composition for making up and/or caring for the skin
NZ719169A (en) Heteroaryl butanoic acid derivatives as lta4h inhibitors
EA201391379A1 (ru) Фармацевтическая композиция для лечения заболевания в полости рта, содержащая ребамипид
MX367561B (es) Composicion cosmetica.
BR112015031885A2 (pt) dispersões estáveis coloidalmente com base em galactomananas modificadas
BR112017027663A2 (pt) método para estabelecer um tampão e método de recuperação de óleo a partir de um reservatório de hidrocarbonetos e formulação
WO2014082027A3 (en) Antioxidant dietary supplement
IN2014DN09584A (pt)
EA201590673A1 (ru) Слоистые двойные гидроксиды

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/08/2011, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2587 DE 04/08/2020, QUANTO AO ITEM (73) ENDERECO DO TITULAR.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2688 DE 12/07/2022, QUANTO AO PRAZO DE VALIDADE: 20 (VINTE) ANOS, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF.